BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease
08. September 2023 08:30 ET
|
BioRestorative Therapies, Inc
--Site activation allows for patients in the State of New York to participate in the BRTX-100 trial— --15 Clinical Sites Identified, 12 of the 15 Activated and Recruiting Subjects MELVILLE,...
BioRestorative Therapies to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14
07. September 2022 07:00 ET
|
BioRestorative Therapies, Inc
BioRestorative Therapies to highlight addition of Phase 2 clinical trial for chronic lumbar disc disease to its mid-stage pipeline. Melville, NY., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BioRestorative...
BioRestorative Therapies Announces Clinical Site Initiation for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
13. Juni 2022 07:00 ET
|
BioRestorative Therapies, Inc
-- First Site Will Enroll First Patient in the Clinical Study-- MELVILLE, NY., June 13, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ:...
BioRestorative Therapies Hosts Principal Investigator Meeting for its BRTX-100® Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease
29. April 2022 08:00 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., April 29, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage biopharmaceutical company focused on stem...
BioRestorative Therapies Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease
18. April 2022 08:00 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y.,, April 18, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...